Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-01-23
2007-01-23
Pak, Michael (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100
Reexamination Certificate
active
09989952
ABSTRACT:
A method for in vitro screening a group of test substances for a ligand using two assay systems, i.e. a cellular or tissue assay system and an enzymatic assay system, is described. First, those test substances are selected which have transcriptional ER-mediated activity measured by an ER-driven reporter gene in the cellular or tissue assay system with an EC50(ER)(half-maximally effective ligand concentration) lower than or equal to 10 nmol/l. Then in an enzymatic assay system the selected test substances having the required transcriptional ER-mediated activity are tested by measuring a physical-chemical interaction (recruitment) of SRC-1 and the ER in the presence of the test substances. The selected ligand activates the ER and induces interaction with the co-present SRC-1 with an E50(ER+SRC)higher than or equal to 100 nmol/l. The ligands found by the inventive screening method are useful for treatment and prevention of neuro-degeneration in the cerebral cortex, especially of age-related cognitive disorders, affective disorders, Alzheimer's diseases and cerebral ischemia/stroke.
REFERENCES:
patent: 99/11760 (1999-03-01), None
patent: 99/18124 (1999-04-01), None
patent: 99 41608 (1999-08-01), None
patent: 99/42108 (1999-08-01), None
patent: 99 42108 (1999-08-01), None
patent: 00 26232 (2000-05-01), None
patent: 00/37681 (2000-06-01), None
V. Patchev et al: “Steroid Hormone-Dependent Organization of . . . ”, R. G. Landes Company, Austin, 1999.
S.E. Alves et al: “Estrogen and Barain Function . . . ”, m. oETTEL and e. Schillinger, Eds., Estrogens and Antiestrogens, Handbook of Experimental Pharmacology, vol. 135/I, Springer, Berlin, Heidelberg, 1999, pp. 315-328.
Vincent Giguere et al: “Estrogen Receptor B: Re-Evaluation of Estrogen . . . ”, Steroids vol. 63, pp. 335-339, 1998.
George G.J.M. Kuiper: “The Novel Estrogen Receptor-B Subtype: Potential Role in the Cell . . . ”FEBS 18558, FEBS Letters 410 (1997), pp. 87-90.
Paul J. Shughrue, et al: “Comparative Distribution of Estrogen Receptor-A . . . ” The Journal of Comparative Neurology, vol. 388, pp. 507-525, 1997.
Sergio A. Onate et al: “Sequence and Characterization of a Coactivator for the Steroid Hormone . . . ” Science, vol. 270, Nov. 1995, pp. 1354-1357.
Daniel Robyr et al: “Nuclear Hormone Receptor Coregulators . . . ”, Molecular Endocrinology, vol. 14, pp. 329-347, 2000.
Els M.J.J. Berns et al: “Predictive Value of SRC-1 for Tamoxifen Response . . . ”, Breast Cancer Research and Treatment, vol. 48, pp. 87-92, 1998.
Simon P. Newman et al: “Cofactor Competition Between the Ligand-Bound Oestrogen Receptor and . . . ” Oncogene 2000, vol. 19, pp. 490-497.
Fernand Labrie et al: “EM-652 (SCH 57068), A Third Generation Serm . . . ” Journal of Steroid Biochemistry and Molecular Biology, Vol. 69, 1999, pp. 51-84.
Jianming Xu et al: “Partial Hormone Resistance in Mice with Disruption . . . ” Science, vol. 279, Mar. 20, 1998, pp. 1922-1925.
O.C. Meijer et al: “Differential Expression and Regional Distribution of . . . ” Endocrinology, vol. 141, No. 6, pp. 2192-2199., 2000.
Xiu Fen Ding et al: “Nuclear Receptor-Binding Sites of Coactivators . . . ”, Molecular Endocrinology, 1998, 12 (2), pp. 302-313.
Yasutomi Kamei et al: “A CBP Integrator Complex Mediates . . . ” Cell, Vo. 86, pp. 403,414, May 3, 1996.
Chelby L. Berger et al: “Guide to Molecular Cloning Techniques”, Methods in Enzymology, vol. 152, pp. 709-713, 1987.
Harvey J. Whitfield et al: “Optimization of CRNA Probe . . . ” Cellular and Molecular Neurobiology, vol. 10, No. 1, 1990, pp. 145-157.
Gaochao Zhou et al: “Nuclear Receptors Have Distict Affinities for Coatovators . . . ” Molecular Endocrinology, vol. 12, pp. 1594-1604, 1998.
Lascombe, L, et al: “Estrogenic Activity Assessment of . . . ”, Environmental Health Perspectives, vol. 108, No. 7, Jul. 2000, pp. 621-629.
Hanstein, B., et al: “Functional Analysis of a Novel Estrogen . . . ”, Molecular Endocrinology, vol. 13, No. 1, Jan. 1999, pp. 129-137.
Zhou, G., “Nuclear Receptors Have Distinct Affinities for Coativators . . . ”, Molecular Endocrinology, Baltimore, MD, US, vol. 12, No. 10, Oct. 1998, pp. 1594-1604.
Martini, P., et al: “Prothymosin Alpha Selectively Enhances Estrogen Receptor . . . ” Molecular and Cellulae Biology, vol. 20, No. 17, Sep. 2000, pp. 6224-6232.
Stenoien, D., et al: “Ligand-Mediated Assembly and Real-Time Cellular Dynamics . . . ” Molecular and Cellular Biology, vol. 21, No. 13, Jul. 2001, pp. 0270-7306.
L. W. Swanson: Brain Maps:Structure of the Rat Brain, A Laboratory Guide with Printed and Electronic Templates for Data, Models and Schematics, Amsterda, Lausanne . . . , 1998.
Langer Gernot
Mitev Youriy
Patchev Vladimir
Wolf Siegmund
Pak Michael
Schering AG
Striker Michael J.
LandOfFree
In Vitro screening for ligands of the estrogen receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In Vitro screening for ligands of the estrogen receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In Vitro screening for ligands of the estrogen receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3748721